Entopsis

Entopsis

生物技术

Miami,Florida 566 位关注者

Simple solutions to complex problems

关于我们

Entopsis utilizes a proprietary material science screening platform to develop cost-effective and impactful products. Our leading solutions: 1) OpsisDx: universal platform to diagnose cancer and various diseases thru urine www.entopsis.com 2) PCRopsis: series of time & cost saving technologies for the life sciences www.PCRopsis.com

网站
https://www.entopsis.com
所属行业
生物技术
规模
11-50 人
总部
Miami,Florida
类型
私人持股
创立
2012

地点

Entopsis员工

动态

  • Entopsis转发了

    查看Alex Dickinson的档案,图片

    Results of a new GRAIL trial published in a press release yesterday. There isn't a peer-reviewed publication referenced (wonder why?) so have to reverse engineer from the PR: Cancer Signal Detected: 37 Early (I-III) stage confirmed: 7 Given that the company's goal is "detecting cancer early when it can be cured" the apparent false discovery rate from this data is = 30/37 = 81%. Pretty bad right? But wait, there's more! This is GRAIL so there's manipulation of the data to hide that the result is far worse. Note that above they are defining "early stage" as all of stages I, II AND III ?? This is of course bullshit: cancer is already spreading at stage III by definition. The cynical manipulation here is clear as in their last study, PATHFINDER, "early stage" was defined as I and II. Even that is generous as technically only stage I is referred to as "early stage". Anyway from that older (back when "early stage" was just I and II) study 48% of all detected cancers where I or II so let's assume in this case that only 3 of the 7 meet a reasonable definition of "early stage"; we now get a false discovery rate of 34/37 = 92%. That's it folks, 9 our of 10 times this test claims to detect "early stage" cancer it's simply wrong ??????

    GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri? Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference - GRAIL

    GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri? Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference - GRAIL

    https://grail.com

  • Entopsis转发了

    查看Ryan Demers的档案,图片

    Global Diagnostics Director, Lung and Liquid Biopsy Strategy at AstraZeneca

    Looking forward to working with SOPHiA Genetics and MSK to decentralize access to precision oncology!

    查看SOPHiA GENETICS的公司主页,图片

    113,071 位关注者

    ?? Don't miss out on our session at the Annual Liquid Biopsy for Precision Oncology Summit in San Diego, CA. ?? Join us on February 29 at 12:00 PM in track B to learn about our collaboration with AstraZeneca and Memorial Sloan Kettering Cancer Center. Together, we're decentralizing precision oncology with MSK-ACCESS?. ??? Save the sate: https://loom.ly/ZSW9L54 T. Scott Reid #LiquidBiopsy #PrecisionMedicine #PrecisionOncology #MSKAccess #LBxSummit

  • Entopsis转发了

    查看Alex Dickinson的档案,图片

    The British Medical Journal has just released a damning report on GRAIL's Galleri test, and the ethics of the Illumina/GRAIL relationship to the NHS: "Experts believe that Galleri has been overhyped and that the current trial is unethical. Concern is mounting over why this particular new screening test has been selected, how it is being evaluated, and whether the bar to success has been set too low.". I've long been skeptical of both the trial and the relationships behind the GRAIL/NHS deal. Symptoms included a series remarkably critical articles by NHS clinicians and the fact that Illumina/GRAIL retained ex-prime minister David Cameron as their lobbyist (https://lnkd.in/gaJHvRWE). This article validates my concerns. If you're interested you should read the article below - it's free - but here are some key quotes: "President of Grail Europe, Harpal Kumar was knighted in 2016 while David Cameron was prime minister. In 2018 Cameron was a paid adviser to Illumina, which spun off Grail in 2016 before finalising the reacquisition of it in 2020. Freedom of information requests from?The BMJ?have shown that Cameron and Illumina staff met then undersecretary of state for business and industry, in March 2021." "Experts also say it is unclear why an NHS trial is being done of a test that showed so little promise in earlier trials. Usually, decisions on what constitutes cost effective NHS screening are made by the independent UK National Screening Committee. Freedom of information requests by?The BMJ?have revealed major disquiet expressed between UK NSC and NHS England regarding Grail." "Documents leaked to?The BMJ?indicate that the criteria being used, unpublished until now, are unsuitable to justify a new national screening programme aimed at saving lives." "Galleri's results are “strikingly low,” says Clare Turnbull, professor of cancer genetics at the Institute of Cancer Research in London. “A good screening test would typically be anticipated to have high sensitivity for early stage cancers, as these are usually the cancers for which surgery would offer the patient a high likelihood of cure (or long term remission),” she adds." "Paul Pharoah, professor of cancer epidemiology at the Cedars-Sinai Medical Center, Los Angeles, agrees: “I do not think that the evidence was sufficiently strong to warrant the trial,” he says. “With a sensitivity for stage I disease of less than 20% overall and only 44% for all stage I-III cancers diagnosed through other tests, I do not think a trial is ethical.” He says it was unclear why “a trial of a test with such little promise” was done." "Richard Sullivan, director of the Institute of Cancer Policy at King’s College London, says that the Grail deal is a “clear cut case of public risk and private profit.”

    Galleri promises to detect multiple cancers—but new evidence casts doubt on this much hyped blood test

    Galleri promises to detect multiple cancers—but new evidence casts doubt on this much hyped blood test

    bmj.com

  • Entopsis转发了

    查看Alex Dickinson的档案,图片

    Interesting! Illumina celebrates the GRAIL divestment by buying Fluent BioSciences Inc. - maker of a single-cell analysis product. Notes: - yay multiomics! - workflow is Fluent sample prep -> NGS -> Fluent software - fits with recent ilmn cfo comment on the importance of NGS as multiomics “readout” - Was an Illumina Ventures investment which isn’t a great antitrust look - press release carefully quotes Steven Barnard noting the illumina is committed to supporting an open “ecosystem” of omics providers - seems to be a direct competitor to 10x Chromium Single Cell - Fluent had previously announced Ultima Genomics as a partner (ouch ??) - Illumina press release wording implies deal already closed implying that there is no automatic HSR antitrust review delay which also implies price was <$120M. Anyway, my congrats to both companies and best of luck! ??????

  • Entopsis转发了

    查看Alex Dickinson的档案,图片

    In 2022 when Illumina and GRAIL leadership where touting how many lives would be saved if only the antitrust authorities got out of the way, here's what was really happening. Please read carefully, shows how this "life saving" test doesn't work: "[With the] San Francisco firefighters, the test did not identify the statistically expected number of cancers, provided false positives for half the cancers it did identify, and missed at least three cases of confirmed cancer. In other words, the exercise showed Galleri to be a disaster." "In this example prominently featured on GRAIL’s website and in marketing materials as an example of how “multi-cancer early detection screening can be critical for those at elevated cancer risk”—GRAIL provided 1,786 screenings to a group of San Francisco firefighters and their family members, a “high risk” group for certain kinds of cancer. During that testing round, which was conducted on December 6, 2022—Galleri generated six false positives and identified only five instances of cancer." "...such a result is alarming in light of the fact that, based on statistical experience, cancer should have been detected in about 29 (not five) of the 1,786 tests. Moreover, of the five instances of where cancer signals were identified, two individuals already knew they had cancer to begin with. Further, all of the instances of detected cancer were at a “late stage,” and where the cancer was too advanced to make a difference for the patients. One firefighter was diagnosed with stage 3 pancreatic cancer and is now in hospice, while another firefighter was diagnosed with lung cancer, which has now metastasized to the brain." "Galleri also missed at least six instances in which the San Francisco firefighters actually had cancer—failing to identify instances of melanoma, prostate cancer, and lymphoma that were identified by private doctors just months after the Galleri test indicated “no cancer signal.” "Further, in one instance in the San Francisco firefighters screening where Galleri generated a false positive, the patient underwent a painful bone marrow biopsy procedure to determine whether the patient did have cancer. In that case, the patient’s bone marrow biopsy procedure, clinically shown to involve “unbearable pain” to the “worst possible pain” a patient can experience, revealed that there was, in fact, no cancer." "The screenings provided to the San Francisco firefighters were an expensive “disappointment.” According to Tony Stefani, the organization’s founder, the screenings demonstrated that the probability of catching an early-stage cancer through the Galleri test was “negligible,” and the screenings only caught “some serious cancers at a later stage,” which likely would have been detected within one or two months without the test. Given the test’s high costs and useless real-world performance, Stefani stated that Galleri was a total “disappointment” and that the foundation had been sold a “bill of goods.” ??????

  • Entopsis转发了

    查看Robert Cardwell的档案,图片

    Chief Strategy Officer, Board Member, Co-Founder

    The PanGIA urine based true liquid biopsy technology has been developed for global impact by diagnosing, monitoring, and managing cancers earlier to save lives using urine as the sample type to create vastly improved availability and scalability in... https://lnkd.in/eRti2m5S #liquidbiopsy #cancerresearch #PanGIA

    PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study

    PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study

    businesswire.com

相似主页

查看职位

融资

Entopsis 共 3 轮

上一轮

未知

US$1,040,000.00

Crunchbase 上查看更多信息